Oral Preparation Deferasirox Dispersible Tablets

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Gold Member Since 2018

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Management System Certification
ISO 9001, ISO 14001, GMP
  • Oral Preparation Deferasirox Dispersible Tablets
  • Oral Preparation Deferasirox Dispersible Tablets
  • Oral Preparation Deferasirox Dispersible Tablets
  • Oral Preparation Deferasirox Dispersible Tablets
Find Similar Products

Basic Info.

Suitable for
Elderly, Adult
State
Solid
Shape
Tablet
Type
Inorganic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Packaging Design
Yes
Transport Package
Carton
Specification
125mg
Trademark
SHIMEN
Origin
Heibi
HS Code
3004909099
Production Capacity
1000000000 Tablets/Year

Product Description

Deferasirox Dispersible Tablet
Product name: Deferasirox Dispersible Tablet
Main ingredients and chemical name: every piece contain: Deferasirox Dispersible Tablet 125mg
Character The product is a white or light yellow tablet.

Indications
It is used to treat chronic iron overload caused by frequent blood transfusions (monthly dose of packed red blood cells > 7 mlkg) in patients with B-thalassemia older than 2 years; For iron overload caused by other transfusion-dependent diseases, the safety and efficacy data of this product in Chinese patients are limited, and it is recommended to use it according to the doctor's advice.
It is also used for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia syndrome.
Pharmacology and toxicology
pharmachologic effect
Deferasirox is an orally active chelating agent that is highly selective for iron (Fe). It is a ligand with three coordination groups that binds to iron in a ratio of 2:1 with high affinity. Although the affinity of deferasirox to zinc and copper is very low, the concentration of these trace metals in the serum still decreases to varying degrees after administration. The clinical significance of these reductions in metal concentrations is unclear. Toxicological studies
Genotoxicity
The Ames test of deferasirox and the chromosomal aberration test of human peripheral blood lymphocytes were negative, and the results of 1 of the 3 rats administered orally in vivo micronucleus test were positive.


Shijiazhuang No.4 Pharmaceutical Co., Ltd. was established in 1948, now it is a large-sized foreign invested enterprise and comprehensive medicine manufacturer in China, the capital is USD58 million, and with more than 3000 employees. The company can manufacture 7 series medicines of more than 100 kinds and specifications including infusions, capsules, granules, tablets, oral liquids and etc with GMP approval by SFDA of China. For the key product of large volume I.V solution, the yearly output has reached more than 1200 million bottles including 40 million bottles packing with the soft plastic bottles in the dosage of 500 ml/ 250 ml /100ml. Some index such as quality, variety, and yearly output are all in the leading position of this field in China.  
The products have been sold to some countries and regions in South America, Africa, and Asia.Oral Preparation Deferasirox Dispersible TabletsOral Preparation Deferasirox Dispersible TabletsOral Preparation Deferasirox Dispersible TabletsOral Preparation Deferasirox Dispersible TabletsOral Preparation Deferasirox Dispersible Tablets

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier